Published in Br J Cancer on June 30, 2015
Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer. Oncotarget (2016) 0.86
Circulating DNA addresses cancer monitoring in non small cell lung cancer patients for detection and capturing the dynamic changes of the disease. Springerplus (2016) 0.83
Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma. Haematologica (2016) 0.79
The liquid biopsy in lung cancer. Genes Cancer (2016) 0.76
Early Change in FDG-PET Signal and Plasma Cell-Free DNA Level Predicts Erlotinib Response in EGFR Wild-Type NSCLC Patients. Transl Oncol (2016) 0.75
The role of total cell-free DNA in predicting outcomes among trauma patients in the intensive care unit: a systematic review. Crit Care (2017) 0.75
Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer. Oncotarget (2016) 0.75
Circulating Tumor Cell and Cell-free Circulating Tumor DNA in Lung Cancer. Chonnam Med J (2016) 0.75
Cell-free DNA as a diagnostic marker for cancer: current insights. Onco Targets Ther (2016) 0.75
Development and Evaluation of a Duplex Real-Time PCR Assay With a Novel Internal Standard for Precise Quantification of Plasma DNA. Ann Lab Med (2017) 0.75
Post surgery circulating free tumor DNA is a predictive biomarker for relapse of lung cancer. Cancer Med (2017) 0.75
Treatment monitoring in metastatic colorectal cancer patients by quantification and KRAS genotyping of circulating cell-free DNA. PLoS One (2017) 0.75
Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38
Circulating mutant DNA to assess tumor dynamics. Nat Med (2007) 10.33
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A (2005) 5.91
DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res (2001) 5.45
Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol (2014) 4.76
Circulating nucleic acids (CNAs) and cancer--a survey. Biochim Biophys Acta (2006) 4.60
Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol (2003) 4.22
About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta (2001) 2.18
Double-stranded DNA in exosomes: a novel biomarker in cancer detection. Cell Res (2014) 2.00
The origin and mechanism of circulating DNA. Ann N Y Acad Sci (2000) 1.87
Excretion of deoxyribonucleic acid by lymphocytes stimulated with phytohemagglutinin or antigen. Proc Natl Acad Sci U S A (1972) 1.84
Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res (2001) 1.76
Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. Clin Chem (2002) 1.72
Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J Clin Oncol (2004) 1.57
Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem (2002) 1.52
The role of macrophages in the in vitro generation of extracellular DNA from apoptotic and necrotic cells. Immunology (2005) 1.28
Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer. Lung Cancer (2008) 1.25
Diagnosis value of serum B7-H3 expression in non-small cell lung cancer. Lung Cancer (2009) 1.23
Comparison of circulating plasma DNA levels between lung cancer patients and healthy controls. J Mol Diagn (2009) 1.19
Quantification of circulating DNA in the plasma and serum of cancer patients. Ann N Y Acad Sci (2004) 1.18
Characterization of circulating DNA in healthy human plasma. Clin Chim Acta (2007) 1.12
Circulating DNA and DNase activity in human blood. Ann N Y Acad Sci (2006) 1.11
Changes in concentration of DNA in serum and plasma during storage of blood samples. Clin Chem (2003) 1.10
p16(INK4A) Hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer. Clin Cancer Res (2002) 1.07
Quantitative analysis of circulating plasma DNA as a tumor marker in thoracic malignancies. Clin Chem (2004) 1.06
Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer. Mol Oncol (2014) 1.01
Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology. J Thorac Oncol (2008) 0.98
Quantitative analysis of cell-free DNA in the plasma of gastric cancer patients. Oncol Lett (2012) 0.98
Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer. Lung Cancer (2009) 0.98
The impact of genetic markers on the diagnosis of lung cancer: a current perspective. J Thorac Oncol (2007) 0.97
Diagnostic and prognostic significance of squamous cell carcinoma antigen in non-small cell lung cancer. Lung Cancer (2001) 0.94
Evaluation of fluorescence-based methods for total vs. amplifiable DNA quantification in plasma of lung cancer patients. J Physiol Pharmacol (2008) 0.92
Cell-free DNA is released from tumor cells upon cell death: a study of tissue cultures of tumor cell lines. J Clin Lab Anal (2003) 0.90
Aging is associated with quantitative and qualitative changes in circulating cell-free DNA: the Vitality 90+ study. Mech Ageing Dev (2010) 0.90
Integrity of cell-free plasma DNA in patients with lung cancer and nonmalignant lung disease. Ann N Y Acad Sci (2008) 0.87
The impact of non-tumor-derived circulating nucleic acids implicates the prognosis of non-small cell lung cancer. J Cancer Res Clin Oncol (2012) 0.85
Cell-surface-bound circulating DNA as a prognostic factor in lung cancer. Ann N Y Acad Sci (2008) 0.85
[Plasma DNA level as a tumor marker in primary lung cancer]. Nihon Kyobu Shikkan Gakkai Zasshi (1990) 0.85
Long-term stability of circulating nucleosomes in serum. Anticancer Res (2010) 0.84
Increased levels of free circulating DNA in patients with idiopathic pulmonary fibrosis. Int J Biol Markers (2010) 0.83
Serum tissue inhibitors of metalloproteinase-1 and -2 in patients with non-small cell lung cancer. Surg Today (2004) 0.82
Circulating nucleic acids in blood of healthy male and female donors. Clin Chem (2005) 0.80
Role of quantitative and qualitative characteristics of free circulating DNA in the management of patients with non-small cell lung cancer. Cell Oncol (Dordr) (2013) 0.79
Quantification of serum SOX2 DNA with FQ-PCR potentially provides a diagnostic biomarker for lung cancer. Med Oncol (2013) 0.78
Plasma DNA levels in spiral CT-detected and clinically detected lung cancer patients: a validation analysis. Lung Cancer (2009) 0.78
Can quantifying free-circulating DNA in plasma be used to identify subjects with high-grade pre-invasive endobronchial lesions? Oncol Lett (2013) 0.76